Clinical trials: Precancerous/Nonmalignant Condition
Actinic Keratosis
Study of SOR007 Ointment for Actinic Keratosis
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007…
- Trial name
- NCT03083470
- Testing
- SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- DFB Soria, LLC
Healthy, Actinic Keratosis
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
The purpose of this phase 1 trial is to investigate the local tolerability on the finger following exposure to PEP005 Gel 0.015% or 0.05% and hand washing once daily, for 2 or 3 consecutive days.
- Trial name
- NCT01302925
- Testing
- PEP005 Gel
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peplin
Actinic Keratosis, Warts
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population.
- Conditions
- Actinic Keratosis, Warts, Basal Cell Carcinoma, Bowens Disease
- Trial name
- NCT00472459
- Testing
- Photodynamic therapy with Metvix 160 mg/g cream
- Where
- 11 sites in Denmark, Germany and 3 more
- Volunteers
- 82 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Barrett Esophagus, Esophageal Dysplasia
WATS3D for the Detection of Esophageal Dysplasia
Patients will be recruited from participating institutions prior to planned routine care EGD with WATS3D brush samples and forceps biopsies.
- Conditions
- Barrett Esophagus, Esophageal Dysplasia, Esophagus Adenocarcinoma
- Trial name
- NCT03008980
- Testing
- Diagnostic Test
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- CDx Diagnostics
Barrett's Esophagus
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
The NvisionVLE® Dysplasia Detection Pilot Study is a prospective, non-randomized trial for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your…
- Trial name
- DDP (NCT02864043)
- Testing
- NvisionVLE with Real Time Targeting, esophagogastroduodenoscopy (EGD)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- NinePoint Medical
Actinic Keratoses
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
This is a double-blind, randomized, placebo-controlled, three treatment parallel study in which normal, healthy men and women (age 45-85) with actinic keratosis will be treated on the face once daily for two weeks with…
- Trial name
- NCT01354717
- Testing
- Brand Carac, Generic 0.5% 5-fluorouracil cream
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Spear Pharmaceuticals
Actinic Keratosis
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis
The purpose of this study is to determine the potential effect of topically applied 3.75% imiquimod cream on atrial ectopy in actinic keratosis (AK) patients.
- Trial name
- NCT01413763
- Testing
- Imiquimod cream 3.75%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medicis Global Service Corporation
Actinic Keratosis
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.
- Trial name
- NCT00659893
- Testing
- PEP005 Topical gel
- Where
- 13 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- Peplin
Actinic Keratosis
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells.
- Trial name
- NCT00335179
- Testing
- Aldara (imiquimod 5% cream), Vehicle cream
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Cervical Intraepithelial Neoplasia
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study.
- Trial name
- NCT03355820
- Testing
- Blood sampling for antibody determination
- Where
- China
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Keratosis
1-Year Follow up to the 1473-IMIQ Study
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study.
- Trial name
- NCT00114023
- Testing
- Imiquimod 5% cream
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Graceway Pharmaceuticals, LLC
Barrett's Esophagus
High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)
The primary objective of this clinical trial is to evaluate the performance of the Nvision Volumetric Laser Endomicroscopy (VLE) system to visualize subsurface tissue in subjects undergoing esophagogastroduodenoscopy (EGD) and to…
- Trial name
- NCT01503411
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- NinePoint Medical
Actinic Keratosis
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups.
- Trial name
- NCT02424305
- Testing
- LEO 43204 gel 0.018%, LEO 43204 gel 0.1%, LEO 43204 gel 0.037%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Twelve Month Follow-Up of CP0108
The purpose of this study is to determine the long-term safety and efficacy of Levulan PDT in subjects with multiple actinic keratosis of the upper extremities who received treatment as part of the DUSA CP0108 study.
- Trial name
- NCT02209012
- Testing
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator
- Where
- 13 sites in United States
- Volunteers
- 206 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Barrett Esophagus
Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE)
Photodynamic therapy (PDT) uses a combination of a drug, porfimer sodium, and a light from a non heated laser. The activation of the drug is done by lighting of abnormal areas using a fiber optic device.
- Trial name
- Oedisse (NCT01209013)
- Testing
- Medlight PDT Balloon, Endoscopy, Endoscopy with biopsy
- Sponsor
- Pinnacle Biologics Inc.
Actinic Keratosis
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.
- Trial name
- NCT01449513
- Testing
- Ingenol mebutate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Cervical Intraepithelial Neoplasia 3
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN…
- Trial name
- CIN3 (NCT01634503)
- Testing
- GX-188E administered by electroporation
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Genexine, Inc.
Actinic Keratosis
Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis
This study is designed to evaluate the pharmacokinetics of solamargine of SR-T100 gel. As safety parameters, adverse events, and vital signs (blood pressure, heart rate, and body temperature) will be recorded.
- Trial name
- NCT02029066
- Testing
- SR-T100 gel
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA